TSE:GENGeneNews Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GeneNews Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume473,148 shsAverage Volume1.48 million shsMarket CapitalizationC$24.65 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesOptions ChainSocial Media GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for GeneNews. Previous Next 2.4 Community Rank Outperform VotesGeneNews has received 87 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGeneNews has received 92 “underperform” votes. (Add your “underperform” vote.)Community SentimentGeneNews has received 51.40% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GeneNews and other stocks. Vote “Outperform” if you believe GEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGeneNews does not currently pay a dividend.Dividend GrowthGeneNews does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GeneNews insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneNews is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneNews is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolTSE:GEN Previous Symbol CUSIPN/A CIKN/A Webwww.genenews.com Phone+1-905-7392030Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$234,592.00 Price / SalesN/A Cash FlowN/A Price / Cash Flow145.00 Book ValueC($0.06) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15 Outstanding SharesN/AMarket CapC$24.65 million Next Earnings DateN/A OptionableOptionable 30 days | 90 days | 365 days | Advanced Chart Receive GEN News and Ratings via Email Sign-up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter. GeneNews (TSE:GEN) Frequently Asked Questions Has GeneNews been receiving favorable news coverage? News coverage about GEN stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. GeneNews earned a news impact score of 1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about GeneNews. Who are some of GeneNews' key competitors? Some companies that are related to GeneNews include Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL), SQI Diagnostics (SQD), Genedrive (GDR), BARD1 Life Sciences (BD1), Sernova (SVA), Imagion Biosys (IBX), LED Medical Diagnostics (LMD), Deepmatter Group (DMTR), Cambridge Cognition (COG), Dorsavi (DVL), VentriPoint Diagnostics (VPT), Smiles Inclusive (SIL) and Imaging Dynamics (IDL). View all competitors. What other stocks do shareholders of GeneNews own? Based on aggregate information from My MarketBeat watchlists, some companies that other GeneNews investors own include StorageVault Canada (SVI), AmerisourceBergen (ABC), American Airlines Group (AAL), Aareal Bank (ARL), Antibe Therapeutics (ATE), Broadcom (AVGO), Aspen Technology (AZPN), British American Tobacco Plc Ads (BATS), Cronos Group (CRON) and Edwards Lifesciences (EW). Who are GeneNews' key executives? GeneNews' management team includes the following people: Mr. James R. Howard-Tripp, Exec. Chairman & CEOMs. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDLProf. Choong-Chin Liew Ph.D., Co-FounderMr. Warren Whitehead, Chief Accountant (Age 67)Mr. David Suria, Sr. Scientist What is GeneNews' stock symbol? GeneNews trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GEN." How do I buy shares of GeneNews? Shares of GEN and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. How big of a company is GeneNews? GeneNews has a market capitalization of C$24.65 million and generates C$234,592.00 in revenue each year. GeneNews employs 15 workers across the globe. What is GeneNews' official website? The official website for GeneNews is www.genenews.com. How can I contact GeneNews? GeneNews' mailing address is 445 Apple Creek Blvd Unit 220, MARKHAM, ON L3R 9X7, Canada. The company can be reached via phone at +1-905-7392030. This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
